Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Safe cosmetics without animal testing? Contributions of the EU Project Sens-it-iv

  • Hans Ulrich Weltzien
  • Emanuela Corsini
  • Sue Gibbs
  • Malin Lindstedt
  • Carl Borrebaeck
  • Petra Budde
  • Peter Schulz-Knappe
  • Hermann-Josef Thierse
  • Stefan F. Martin
  • Erwin L. Roggen
Publiceringsår: 2009
Språk: Engelska
Sidor: 41-48
Publikation/Tidskrift/Serie: Journal für Verbraucherschütz und Lebensmittelsicherheit
Volym: 4
Nummer: Suppl. 2
Dokumenttyp: Artikel i tidskrift
Förlag: Birkhaüser


The 7th Ammendment to the Cosmetics Directive of the European Commission (Directive 76/768/EEC2) bans the marketing of cosmetics containing animal-tested ingredients since March 2009. Excepted are only tests for repeated dose toxicity, for which the animal ban will come into effect by 2013. One major concern for cosmetics, i.e. the risk of containing skin (contact) sensitizers, has in the past been addressed almost exclusively by animal testing. It is this problem attracting the central interest of the integrated research project Sens-it-iv (Novel Testing Strategies for in vitro Assessment of Allergens, ), funded by the EC within framework 6 since October 2005. Here, the 28 Sens-it-iv partners from 10 European States present the 5 most promising types of in vitro assays selected for further refinement. These are: (1) a human epidermal equivalent (EE) model to rank contact allergens according to their sensitizing potency, (2) identification of contact sensitizers, including pro-haptens, through intracellular production of IL-18 by the human keratinocyte cell line NCTC 2544, (3) determination of activation markers such as CD86, CD54 and most prominently CXCL8 (IL-8) on/in dendritic cell lines, (4) contact sensitizer-specific migration of MUTZ Langerhans cells towards the chemokine CXCL12, and (5) the allergen-specific activation and proliferation of na < ve human T cells. Ongoing genomic and proteomic experiments are in the process of identifying larger sensitizer-specific biological marker signatures to be integrated into the above assays. We hope to supply the European control agencies with a basis for further validation of in vitro assays by the end of 2010.


  • Immunology in the medical area
  • Allergy
  • Contact
  • Sensitizer
  • In vitro
  • Alternative
  • Animal
  • Cosmetic


  • ISSN: 1661-5867

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen